Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim T Arndt

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2015
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer TreatmentTodd VanArsdale, Chris Boshoff, Kim T Arndt, et al.
The Journal of Biological Chemistry|January 1, 2004
Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4Qiang Zhao, Frank Boschelli, Avrom J Caplan, et al.
Cell Stress & Chaperones|August 19, 2010
A cell-based screen for inhibitors of protein folding and degradationFrank Boschelli, Jennifer M Golas, Roseann Petersen, et al.
Cell Cycle (Georgetown, Tex.)|December 28, 2020
Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cellsReeja S Maskey, Fang Wang, Elyssa Lehman, et al.
Yeast (Chichester, England)|February 11, 2005
Physiological effects of unassembled chaperonin Cct subunits in the yeast Saccharomyces cerevisiaeM Anaul Kabir, Joanna Kaminska, George B Segel, et al.
Bioorganic & Medicinal Chemistry Letters|July 31, 2009
2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancerZecheng Chen, Aranapakam M Venkatesan, Christoph M Dehnhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2015
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast CancerSuzanne E Wardell, Matthew J Ellis, Holly M Alley, et al.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2015
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer TreatmentTodd VanArsdale, Chris Boshoff, Kim T Arndt, et al.
The Journal of Biological Chemistry|January 1, 2004
Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4Qiang Zhao, Frank Boschelli, Avrom J Caplan, et al.
Cell Stress & Chaperones|August 19, 2010
A cell-based screen for inhibitors of protein folding and degradationFrank Boschelli, Jennifer M Golas, Roseann Petersen, et al.
Cell Cycle (Georgetown, Tex.)|December 28, 2020
Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cellsReeja S Maskey, Fang Wang, Elyssa Lehman, et al.
Yeast (Chichester, England)|February 11, 2005
Physiological effects of unassembled chaperonin Cct subunits in the yeast Saccharomyces cerevisiaeM Anaul Kabir, Joanna Kaminska, George B Segel, et al.
Bioorganic & Medicinal Chemistry Letters|July 31, 2009
2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancerZecheng Chen, Aranapakam M Venkatesan, Christoph M Dehnhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2015
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast CancerSuzanne E Wardell, Matthew J Ellis, Holly M Alley, et al.
Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.
Pageof 1